Several cardiovascular risk factors, such as advanced age and smoking history, are prevalent among lung cancer patients at the time of the diagnosis and increase their risk of future heart disease, ...
Carey, a sustainable tourism consultant, is heading to the House of Commons on February 26 and to the Scottish Parliament on ...
The lack of NHS funded testing for this type of cancer in Scotland means patients are denied targeted treatments unless they pay for tests privately.
where cancer from another part of the body spreads to the liver. Hepatocellular Carcinoma (HCC) stands out as the predominant form of primary liver cancer, particularly prevalent among individuals ...
This case report presents a 57-year-old male with hepatocellular carcinoma ... A follow-up CT on November 27, 2023, indicated a newly developed abnormal enhancing nodule at the liver apex compared to ...
A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...
Mechanistically, the authors show that inhibiting PLEC results in a disorganized cytoskeleton, deficiency in cell migration, and changes in cancer-relevant signaling pathways. This study demonstrates ...
The median progression-free survival per RECICL was 10.8 months in the combination arm and 3.2 months in the TACE-alone arm. Adding camrelizumab and rivoceranib to transarterial chemoembolization ...
ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer
1Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom. 2Department of Translational Medicine (DIMET), University of Piemonte ...
aDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China bDepartment of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China ...
“The casdozo data in HCC demonstrate translation of the preclinical data in liver cancer to first-line HCC cancer patients with efficacy and a favorable safety profile. These data support the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results